Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study

已完结 10 由老谈发布于 2026/4/8 21:35:24

DOI:10.1016/s0140-6736(24)02551-0
作者：Bruno Sangro, Masatoshi Kudo, Joseph P Erinjeri, Shukui Qin, Zhenggang Ren, Stephen L Chan, Yasuaki Arai, Jeong Heo, Anh Mai, Jose Escobar, Yamil Alonso Lopez Chuken, Jung-Hwan Yoon, Won Young Tak, Va
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：BackgroundTransarterial chemoembolisation (TACE) is standard of care for patients with unresectable hepatocellular carcinoma that is amenable to embolisation; however, median progression-fre

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库Microenvironment Engineering Vinylene-Linked Covalent Organic Frameworks for Highly Efficient CO2 Photoreduction.